期刊
BRAIN RESEARCH
卷 1677, 期 -, 页码 47-57出版社
ELSEVIER
DOI: 10.1016/j.brainres.2017.09.022
关键词
Migraine; Spreading depression; Microglia; Inflammation; Neuroinflammation; Insulin-like growth factor-1; Neurotherapeutics
资金
- National Institute of Neurological Disorders and Stroke [NS-019108]
- National Institute of Health Common Fund, through the Office of Strategic Coordination/Office of the Director
- Innovation Fund from Polsky Center for Entrepreneurship and Innovation at the University of Chicago
- [5UH 3 TR000918UH-04]
- [3UH3TR000918-04S1]
- [3UH3TR000918-03S1]
Spreading depression (SD) is a wave of cellular depolarization that travels slowly through susceptible gray matter brain areas. SD is the most likely cause of migraine aura and perhaps migraine pain, and is a well-accepted animal model of migraine. Identification of therapeutics that can prevent SD may have clinical relevance toward migraine treatment. Here we show that insulin-like growth factor-1 (IGF-1) significantly inhibited neocortical SD in vivo after intranasal delivery to rats. A single dose of IGF-1 inhibited SD within an hour, and continued to protect for at least seven days thereafter. A two-week course of IGF-1, administered every third day, further decreased SD susceptibility and showed no aberrant effects on glial activation, nasal mucosa, or serum markers of toxicity. SD begets SD in vitro by mechanisms that involve microglial activation. We add to this relationship by showing that recurrent SD in vivo increased susceptibility to subsequent SD, and that intervention with IGF-1 significantly interrupted this pathology. These findings support nasal administration of IGF-1 as a novel intervention capable of mitigating SD susceptibility, and as a result, potentially migraine. (C) 2017 Elsevier B.V. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据